A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas

Minesh Mehta

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas

Minesh Mehta

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	155
State	Published - Dec 1 2021

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{503600acccf346b989503591b54f2d45,

title = "A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas",

author = "Minesh Mehta",

note = "Journal of Neuro-Oncology (2021) 155(3):297-306",

year = "2021",

month = dec,

day = "1",

language = "American English",

volume = "155",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas

AU - Mehta, Minesh

N1 - Journal of Neuro-Oncology (2021) 155(3):297-306

PY - 2021/12/1

Y1 - 2021/12/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4287

M3 - Article

VL - 155

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas

Access to Document

Other files and links

Cite this